Delivery Order SPE2DB22D3011-SPE2DB25FQ2MM
- Not listed
- The Defense Logistics Agency awarded a $12,851.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The company...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,823.64 for 50-unit vials of Xeomin, a botulinum toxin injection used for therapeutic and cosmetic applications. This firm fixed-price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a non-competitive set-aside award issued under the company's larger indefinite delivery contract. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 14, 2025, with completion targeted for September 5, 2025, represents a non-competitive set-aside award drawn from a larger contract vehicle. The product will be performed and delivered from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 20, 2025, carries a ceiling value of $13,968.50 and is scheduled for completion by September 11, 2025. The contract was competitively awarded without a set-aside designation, with performance taking place at AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic applications. This $10,057.32 firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The award, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xeomin 200 Unit Vials, a botulinum toxin product used for medical purposes. This firm fixed price delivery order, valued at approximately $25.1K, is scheduled for completion by August 21, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The contract was competitively awarded with no set-aside designation, reflecting the vendor's established...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2MMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,352.16 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications within military and federal healthcare systems. The contract, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, carries a firm fixed price and was competitively awarded without any set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This delivery order represents a small-value transaction within AmerisourceBergen Drug Corp's extensive portfolio of federal pharmaceutical supply contracts with the DLA. The company holds a significant Indefinite Delivery Contract (IDC) designated SPE2DX valued at $999.99 million through December 2026, which serves as the underlying vehicle enabling the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. This particular Xeomin delivery order exemplifies the company's critical role in fulfilling federal medical procurement requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/29/25 |